To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 158 participants.

Also called NCT01935167

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 158 participants (enrolled count) (from the registry)
Sponsor
Dong Wha Pharmaceutical Co. Ltd. (from the registry)
Registry
  • NCT NCT01935167
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01935167. Randomized; double masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2014-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy
Condition
Diabetic Nephropathy
Intervention (Drug)
DW1029M 600mg
Intervention (Drug)
DW1029M 1200mg
Intervention (Drug)
Placebo
Lead sponsor
Dong Wha Pharmaceutical Co. Ltd. (class: industry)

Record details

Record id
cardio:ct-nct01935167
Content hash
30b28a67cedca1fd6f7fd3c40ab7ecb5ba64e0e0a2e9054b80690d8c4da5e353